Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bcp.15666
Keywords
acute kidney injury; biomarker; cisplatin; metabolomics
Categories
Ask authors/readers for more resources
Metabolomics analysis identified potential biomarkers, including glycine, hippuric acid sulfate, 3-hydroxydecanedioc acid, and suberate, for predicting cisplatin-induced acute kidney injury.
AimCisplatin causes acute kidney injury (AKI) in approximately one third of patients. Serum creatinine and urinary output are poor markers of cisplatin-induced AKI. Metabolomics was utilized to identify predictive or early diagnostic biomarkers of cisplatin-induced AKI. MethodsThirty-one adult head and neck cancer patients receiving cisplatin (dose >= 70 mg/m(2)) were recruited for metabolomics analysis. Urine and serum samples were collected prior to cisplatin (pre), 24-48 h after cisplatin (24-48 h) and 5-14 days (post) after cisplatin. Based on serum creatinine concentrations measured at the post timepoint, 11/31 patients were classified with clinical AKI. Untargeted metabolomics was performed using liquid chromatography-mass spectrometry (LC-MS). ResultsMetabolic discrimination was observed between AKI patients and no AKI patients at all timepoints. Urinary glycine, hippuric acid sulfate, 3-hydroxydecanedioc acid and suberate were significantly different between AKI patients and no AKI patients prior to cisplatin infusion. Urinary glycine and hippuric acid sulfate were lower (-2.22-fold and -8.85-fold), whereas 3-hydroxydecanedioc acid and suberate were higher (3.62-fold and 1.91-fold) in AKI patients relative to no AKI patients. Several urine and serum metabolites were found to be altered 24-48 h following cisplatin infusion, particularly metabolites involved with mitochondrial energetics. ConclusionsWe propose glycine, hippuric acid sulfate, 3-hydroxydecanedioc acid and suberate as predictive biomarkers of predisposition to cisplatin-induced AKI. Metabolites indicative of mitochondrial dysfunction may serve as early markers of subclinical AKI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available